Journey Medical Corporation (DERM)
NASDAQ: DERM · Real-Time Price · USD
6.68
+0.22 (3.41%)
Aug 18, 2026, 1:03 PM EDT - Market open
Journey Medical Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 66.85 | 61.24 | 55.13 | 59.66 | 71 | 63.13 |
Other Revenue | 1.33 | 0.62 | 1 | 19.52 | 2.67 | - |
| 68.18 | 61.86 | 56.13 | 79.18 | 73.67 | 63.13 | |
Revenue Growth | 20.89% | 10.20% | -29.11% | 7.48% | 16.69% | 41.77% |
Cost of Revenue | 23.56 | 20.92 | 20.88 | 22.89 | 30.78 | 25.58 |
Gross Profit | 44.63 | 40.93 | 35.26 | 56.29 | 42.89 | 37.55 |
Selling, General & Admin | 42.91 | 44.37 | 40.2 | 43.91 | 59.47 | 39.83 |
Research & Development | 0.5 | 0.48 | 9.86 | 7.54 | 10.94 | 16.56 |
Amortization of Goodwill & Intangibles | 4.22 | 4.26 | 3.42 | 3.77 | - | - |
Other Operating Expenses | - | - | -4.55 | - | - | - |
Operating Expenses | 47.63 | 49.11 | 48.93 | 55.22 | 70.41 | 56.39 |
Operating Income | -3.01 | -8.17 | -13.68 | 1.07 | -27.52 | -18.84 |
Interest Expense | -3.67 | -3.7 | -2.7 | -1.7 | -2.02 | -7.03 |
Interest & Investment Income | 0.61 | 0.59 | 0.76 | 0.32 | 0.06 | 0 |
Currency Exchange Gain (Loss) | -0.03 | -0.09 | -0.12 | -0.18 | -0.09 | - |
Other Non Operating Income (Expenses) | - | - | - | - | - | -0.45 |
EBT Excluding Unusual Items | -6.09 | -11.37 | -15.74 | -0.49 | -29.57 | -26.32 |
Merger & Restructuring Charges | - | - | - | - | - | -6.5 |
Asset Writedown | - | - | - | -3.14 | - | - |
Other Unusual Items | - | - | 1.13 | - | - | -9.54 |
Pretax Income | -6.09 | -11.37 | -14.61 | -3.63 | -29.57 | -42.36 |
Income Tax Expense | 0.02 | 0.06 | 0.06 | 0.22 | 0.06 | 1.63 |
Net Income | -6.1 | -11.43 | -14.67 | -3.85 | -29.63 | -43.99 |
Net Income to Common | -6.1 | -11.43 | -14.67 | -3.85 | -29.63 | -43.99 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 27 | 24 | 20 | 18 | 18 | 10 |
Shares Outstanding (Diluted) | 27 | 24 | 20 | 18 | 18 | 10 |
Shares Change | 21.63% | 19.90% | 12.06% | 4.00% | 72.05% | -5.96% |
EPS (Basic) | -0.23 | -0.47 | -0.72 | -0.21 | -1.69 | -4.32 |
EPS (Diluted) | -0.23 | -0.47 | -0.72 | -0.21 | -1.69 | -4.32 |
EPS Growth | - | - | - | - | - | - |
Free Cash Flow | -7.49 | -12.44 | -9.13 | 5.24 | -13.53 | -2.18 |
Free Cash Flow Per Share | -0.28 | -0.51 | -0.45 | 0.29 | -0.77 | -0.21 |
Gross Margin | 65.45% | 66.17% | 62.80% | 71.09% | 58.23% | 59.48% |
Operating Margin | -4.41% | -13.21% | -24.37% | 1.35% | -37.35% | -29.84% |
Profit Margin | -8.95% | -18.48% | -26.14% | -4.87% | -40.22% | -69.68% |
Free Cash Flow Margin | -10.99% | -20.11% | -16.26% | 6.62% | -18.37% | -3.45% |
EBITDA | 1.22 | -3.91 | -10.25 | 4.84 | -23.24 | -16.37 |
EBITDA Margin | 1.78% | -6.33% | -18.27% | 6.11% | -31.55% | -25.92% |
D&A For EBITDA | 4.22 | 4.26 | 3.42 | 3.77 | 4.28 | 2.47 |
EBIT | -3.01 | -8.17 | -13.68 | 1.07 | -27.52 | -18.84 |
EBIT Margin | -4.41% | -13.21% | -24.37% | 1.35% | -37.35% | -29.84% |
Revenue as Reported | 68.18 | 61.86 | 56.13 | 79.18 | 73.67 | 63.13 |